+18%

est. 2Y upside i

HealthcareSeries D+

Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We're not simply focused on helping you live longer. We're focused on making every year the best it can be. Because how well you live is as important as how long you live.

Rank

#3003

Sector

Preventive Healthcare

Est. Liquidity

~4Y

Data Quality

Data: Low

Biograph is a credible longevity brand with premium subscription economics, a well-known co-founder in Peter Attia, and $25M in revenue — but the absence of a disclosed valuation, growth rate, and profitability data makes it impossible to independently underwrite the equity.

Last updated: May 14, 2026

Bull (22%)+90%

Longevity sector momentum accelerates and Biograph scales to $60M+ ARR by 2028 through multi-city clinic expansion and its Peter Attia brand halo, attracting a strategic acquirer (large insurer or integrated health system) or commanding a pre-IPO round at a $350M+ valuation. Common stockholders realize ~90% upside after the $53.9M liquidation preference stack is cleared.

Base (53%)+20%

Biograph reaches ~$40M revenue by 2028 with measured clinic openings, but high capital intensity and dilutive fundraising keep common-stock value near $175-200M implied exit, yielding modest ~20% upside after preference stack overhang. A liquidity event within the 2-year horizon is unlikely; employees wait 4+ years for realized gains.

Bear (25%)-50%

Regulatory headwinds — ACR criticism of preventive full-body scanning gaining institutional traction — slow member enrollment and compress the $7,500-$15,000 price point, forcing a flat or down round at sub-$100M valuation. With $53.9M in liquidation preferences senior to common stock, employee equity is largely eroded, producing a ~-50% real-dollar loss.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

3590%

Total disclosed funding of $53.9M sits senior to common stock as liquidation preferences; against an estimated valuation of ~$150M this consumes approximately 36% of any exit proceeds before employees receive a dollar.

Dilution Risk

high

High capital intensity with no confirmed profitability signals continued fundraising need, with each future round likely adding 15-25% dilution to existing common holders.

Secondary Liquidity

limited

No known secondary market program or tender offer history; employees should treat this equity as fully illiquid until a formal M&A or IPO event, realistically 4+ years out.

Other — 10 roles

View all 10 open roles at Biograph →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Biograph's data — designed to show you've done your homework.

  • 1

    “What is the post-money valuation from the most recent Later Stage VC round, and what percentage of fully diluted shares would my grant represent after accounting for the option pool?”

  • 2

    “What is the month-over-month or year-over-year member growth rate, and what is the target clinic footprint and revenue run-rate for the end of 2026?”

  • 3

    “What is the current cash runway given high capital intensity, and is the company planning a Series D or any near-term secondary / tender offer that would give employees a liquidity window?”

Community

Valuation Sentiment

Our model estimates +18% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.